Losartan potassium 50MG [F-6]; efficacy and biochemical evaluation of pharmaceutical optimized with essential hypertension

ABSTRACT

Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. It suppresses the effects of angitensin II at its receptors, thereby blocking the rennin-angiotensin system. The rennin-angiotensin system plays a crucial role in the control of blood pressure, and in particular it is felt to play crucial role in hypertension. The objective of this double-blind, comparative study evaluating efficacy and biochemical effects of optimized Losartan Potassium 50mg [F-6] as monotherapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from January 2010 to August 2010. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive once Losartan Potassium 50mg [F-6] daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. The patients treated with optimized Losartan potassium [F-6] alone, blood pressure reduction was lower, although significant; reaching values of 140.9 +/- 11.3 / m88.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment.. No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Losartan potassium [F-6] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks